Share-based Payment Arrangement, Expense of Immunovant, Inc. from 31 Dec 2018 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Immunovant, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2018 to 30 Sep 2025.
  • Immunovant, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $13,186,000, a 4% increase year-over-year.
  • Immunovant, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $54,916,000, a 19% increase year-over-year.
  • Immunovant, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $49,463,000, a 21% increase from 2023.
  • Immunovant, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $41,013,000, a 28% increase from 2022.
  • Immunovant, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $31,966,000, a 3.6% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Immunovant, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $54,916,000 $13,186,000 +$501,000 +4% 01 Jul 2025 30 Sep 2025 10-Q 10 Nov 2025 2026 Q2
Q2 2025 $54,415,000 $18,395,000 +$4,952,000 +37% 01 Apr 2025 30 Jun 2025 10-Q 11 Aug 2025 2026 Q1
Q1 2025 $49,463,000 $11,686,000 +$2,024,000 +21% 01 Jan 2025 31 Mar 2025 10-K 29 May 2025 2025 FY
Q4 2024 $47,439,000 $11,649,000 +$1,452,000 +14% 01 Oct 2024 31 Dec 2024 10-Q 06 Feb 2025 2025 Q3
Q3 2024 $45,987,000 $12,685,000 +$2,184,000 +21% 01 Jul 2024 30 Sep 2024 10-Q 10 Nov 2025 2026 Q2
Q2 2024 $43,803,000 $13,443,000 +$2,790,000 +26% 01 Apr 2024 30 Jun 2024 10-Q 11 Aug 2025 2026 Q1
Q1 2024 $41,013,000 $9,662,000 +$2,158,000 +29% 01 Jan 2024 31 Mar 2024 10-K 29 May 2025 2025 FY
Q4 2023 $38,855,000 $10,197,000 +$1,341,000 +15% 01 Oct 2023 31 Dec 2023 10-Q 06 Feb 2025 2025 Q3
Q3 2023 $37,514,000 $10,501,000 +$2,450,000 +30% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2025 Q2
Q2 2023 $35,064,000 $10,653,000 +$3,098,000 +41% 01 Apr 2023 30 Jun 2023 10-Q 06 Aug 2024 2025 Q1
Q1 2023 $31,966,000 $7,504,000 -$4,196,000 -36% 01 Jan 2023 31 Mar 2023 10-K 29 May 2025 2025 FY
Q4 2022 $36,162,000 $8,856,000 -$1,098,000 -11% 01 Oct 2022 31 Dec 2022 10-Q 12 Feb 2024 2024 Q3
Q3 2022 $37,260,000 $8,051,000 +$382,000 +5% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2024 Q2
Q2 2022 $36,878,000 $7,555,000 +$3,735,000 +98% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2024 Q1
Q1 2022 $33,143,000 $11,700,000 +$6,279,000 +116% 01 Jan 2022 31 Mar 2022 10-K 22 May 2023 2023 FY
Q4 2021 $26,864,000 $9,954,000 +$3,962,000 +66% 01 Oct 2021 31 Dec 2021 10-Q 03 Feb 2023 2023 Q3
Q3 2021 $22,902,000 $7,669,000 +$4,362,000 +132% 01 Jul 2021 30 Sep 2021 10-Q 04 Nov 2022 2023 Q2
Q2 2021 $18,540,000 $3,820,000 -$98,000 -2.5% 01 Apr 2021 30 Jun 2021 10-Q 05 Aug 2022 2023 Q1
Q1 2021 $18,638,000 $5,421,000 +$3,621,000 +201% 01 Jan 2021 31 Mar 2021 10-K 08 Jun 2022 2022 FY
Q4 2020 $15,017,000 $5,992,000 +$4,660,000 +350% 01 Oct 2020 31 Dec 2020 10-Q 04 Feb 2022 2022 Q3
Q3 2020 $10,357,000 $3,307,000 +$188,000 +6% 01 Jul 2020 30 Sep 2020 10-Q 05 Nov 2021 2021 Q2
Q2 2020 $10,169,000 $3,918,000 +$3,381,000 +630% 01 Apr 2020 30 Jun 2020 10-Q 09 Aug 2021 2021 Q1
Q1 2020 $6,788,000 $1,800,000 01 Jan 2020 31 Mar 2020 10-K 01 Jun 2021 2020 FY
Q4 2019 $1,332,000 +$1,320,000 01 Oct 2019 31 Dec 2019 10-Q 16 Feb 2021 2021 Q3
Q3 2019 $3,119,000 01 Jul 2019 30 Sep 2019 10-Q 12 Nov 2020 2021 Q2
Q2 2019 $537,000 01 Apr 2019 30 Jun 2019 10-Q 12 Aug 2020 2020 Q1
Q4 2018 $12,000* 01 Oct 2018 31 Dec 2018 10-Q 14 Feb 2020 2019 Q3

Immunovant, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $49,463,000 +$8,450,000 +21% 01 Apr 2024 31 Mar 2025 10-K 29 May 2025 2025 FY
2023 $41,013,000 +$9,047,000 +28% 01 Apr 2023 31 Mar 2024 10-K 29 May 2025 2025 FY
2022 $31,966,000 -$1,177,000 -3.6% 01 Apr 2022 31 Mar 2023 10-K 29 May 2025 2025 FY
2021 $33,143,000 +$14,505,000 +78% 01 Apr 2021 31 Mar 2022 10-K 22 May 2023 2023 FY
2020 $18,638,000 +$11,850,000 +175% 01 Apr 2020 31 Mar 2021 10-K 08 Jun 2022 2022 FY
2019 $6,788,000 +$6,757,000 +21797% 01 Apr 2019 31 Mar 2020 10-K 01 Jun 2021 2020 FY
2018 $31,000 01 Apr 2018 31 Mar 2019 10-K 29 Jun 2020 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.